• Something wrong with this record ?

Nurse-led sedation for transfemoral transcatheter aortic valve implantation seems safe for a selected patient population

V. Kočka, M. Nováčková, L. Kratochvílová, A. Širáková, J. Sulženko, T. Buděšínský, M. Bystroń, M. Neuberg, P. Mašek, F. Bednář, M. Stern, AP. Toušek

. 2022 ; 24 (Suppl B) : B23-B27. [pub] 20220330

Language English Country Great Britain

Document type Journal Article

Transcatheter aortic valve implantation (TAVI) has become a high-volume procedure with increasing demands on hospital resources. Local anaesthesia with sedation supervised by an anaesthesiology team is the current standard of care. We aimed to describe our experience with a simplified, nurse-led sedation (NLS) protocol. This study enrolled 128 consecutive patients who underwent transfemoral TAVI with self-expandable Evolut R prosthesis between November 2019 and April 2021. Operators selected 50% of patients for NLS based on the clinical expectation of lower risk of procedural difficulties. Nurse-led sedation protocol demanded only mild to moderate levels of sedation. The clinical outcomes were determined from the local TAVI registry and the national mortality database. Baseline patient characteristics were similar in the NLS (n = 64) and anaesthesiologist-led sedation (ALS) (n = 64) groups except higher prevalence of diabetes mellitus (48.4% vs. 31.3%, P = 0.035) and peripheral vascular disease (20.3% vs. 7.8%, P = 0.036) in the ALS group. There was a trend for the larger prostheses used in the ALS group (P = 0.058). The procedural results did not differ, and coronary care team backup was rarely needed in the NLS group (6% of patients). The in-hospital outcomes were identical from both clinical and echocardiography perspectives, and 30-day mortality was low in both groups (1.5%). For the NLS group, preparation in the catheterization laboratory was quicker by 6.4 min (P = 0.01), and intensive care unit stay was shorter (2.03 vs. 3.48 days, P = 0.001). In conclusion, the NLS for the selected transfemoral TAVI population seems safe.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017488
003      
CZ-PrNML
005      
20220720100241.0
007      
ta
008      
220718s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/eurheartjsupp/suac004 $2 doi
035    __
$a (PubMed)35370506
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Kočka, Viktor $u Department of Cardiology, Third Faculty of Medicine, University Hospital Královské Vinohrady, Charles University, Šrobárova 50, Prague 100 34, Czech Republic
245    10
$a Nurse-led sedation for transfemoral transcatheter aortic valve implantation seems safe for a selected patient population / $c V. Kočka, M. Nováčková, L. Kratochvílová, A. Širáková, J. Sulženko, T. Buděšínský, M. Bystroń, M. Neuberg, P. Mašek, F. Bednář, M. Stern, AP. Toušek
520    9_
$a Transcatheter aortic valve implantation (TAVI) has become a high-volume procedure with increasing demands on hospital resources. Local anaesthesia with sedation supervised by an anaesthesiology team is the current standard of care. We aimed to describe our experience with a simplified, nurse-led sedation (NLS) protocol. This study enrolled 128 consecutive patients who underwent transfemoral TAVI with self-expandable Evolut R prosthesis between November 2019 and April 2021. Operators selected 50% of patients for NLS based on the clinical expectation of lower risk of procedural difficulties. Nurse-led sedation protocol demanded only mild to moderate levels of sedation. The clinical outcomes were determined from the local TAVI registry and the national mortality database. Baseline patient characteristics were similar in the NLS (n = 64) and anaesthesiologist-led sedation (ALS) (n = 64) groups except higher prevalence of diabetes mellitus (48.4% vs. 31.3%, P = 0.035) and peripheral vascular disease (20.3% vs. 7.8%, P = 0.036) in the ALS group. There was a trend for the larger prostheses used in the ALS group (P = 0.058). The procedural results did not differ, and coronary care team backup was rarely needed in the NLS group (6% of patients). The in-hospital outcomes were identical from both clinical and echocardiography perspectives, and 30-day mortality was low in both groups (1.5%). For the NLS group, preparation in the catheterization laboratory was quicker by 6.4 min (P = 0.01), and intensive care unit stay was shorter (2.03 vs. 3.48 days, P = 0.001). In conclusion, the NLS for the selected transfemoral TAVI population seems safe.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Nováčková, Markéta $u Department of Cardiology, Third Faculty of Medicine, University Hospital Královské Vinohrady, Charles University, Šrobárova 50, Prague 100 34, Czech Republic
700    1_
$a Kratochvílová, Lenka $u Medtronic Czechia, Prosecká 66, Prague 190 00, Czech Republic
700    1_
$a Širáková, Andrea $u Department of Cardiology, Third Faculty of Medicine, University Hospital Královské Vinohrady, Charles University, Šrobárova 50, Prague 100 34, Czech Republic
700    1_
$a Sulženko, Jakub $u Department of Cardiology, Third Faculty of Medicine, University Hospital Královské Vinohrady, Charles University, Šrobárova 50, Prague 100 34, Czech Republic
700    1_
$a Buděšínský, Tomáš $u Department of Cardiology, Third Faculty of Medicine, University Hospital Královské Vinohrady, Charles University, Šrobárova 50, Prague 100 34, Czech Republic
700    1_
$a Bystroń, Marian $u Department of Cardiology, Third Faculty of Medicine, University Hospital Královské Vinohrady, Charles University, Šrobárova 50, Prague 100 34, Czech Republic
700    1_
$a Neuberg, Marek $u Medtronic Czechia, Prosecká 66, Prague 190 00, Czech Republic
700    1_
$a Mašek, Petr $u Medtronic Czechia, Prosecká 66, Prague 190 00, Czech Republic
700    1_
$a Bednář, František $u Department of Cardiology, Third Faculty of Medicine, University Hospital Královské Vinohrady, Charles University, Šrobárova 50, Prague 100 34, Czech Republic
700    1_
$a Stern, Michael $u Department of Anaesthesia and Intensive Care Medicine, Third Faculty of Medicine, University Hospital Královské Vinohrady, Charles University, Šrobárova 50, Prague 100 34, Czech Republic
700    1_
$a Toušek, And Petr $u Department of Cardiology, Third Faculty of Medicine, University Hospital Královské Vinohrady, Charles University, Šrobárova 50, Prague 100 34, Czech Republic
773    0_
$w MED00005247 $t European heart journal supplements : journal of the European Society of Cardiology $x 1520-765X $g Roč. 24, Suppl B (2022), s. B23-B27
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35370506 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220718 $b ABA008
991    __
$a 20220720100236 $b ABA008
999    __
$a ind $b bmc $g 1816611 $s 1168730
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 24 $c Suppl B $d B23-B27 $e 20220330 $i 1520-765X $m European heart journal supplements $n Eur Heart J Suppl $x MED00005247
LZP    __
$a Pubmed-20220718

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...